At what enterprise value was SCHÜLKE acquired in 2020?

During the acquisition of SCHÜLKE by EQT PARTNERS in 2020, the transaction's Enterprise Value is estimated to be in the range of 500M - 1.5b EUR.

What was the EV/EBITDA of SCHÜLKE when it was acquired by EQT PARTNERS?

The estimated EV/EBITDA multiple for SCHÜLKE is in the range of 10x - 18x.

When was SCHÜLKE acquired by EQT PARTNERS?

SCHÜLKE was acquired by EQT PARTNERS in 2020.

What was the revenue of SCHÜLKE at the time of the deal?

The revenue of SCHÜLKE at the time of the deal is estimated to be in the range of 250M - 500M EUR.

What was the EBITDA of SCHÜLKE during the acquisition?

SCHÜLKE's EBITDA is estimated to be in the range of 50M - 100M EUR.

How is the data for the SCHÜLKE acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the SCHÜLKE deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://eqtgroup.com/about/current-portfolio/schulke

← DATABASE

Home Database Healthcare & PharmaSCHÜLKE

09/2020

SCHÜLKE acquired by EQT PARTNERS

GERMANY Life Sciences / Medical Devices / Medical Consumables EV 500M - 1.5b EUR

Context

EQT completed the acquisition of 100% of Schülke from its parent company, Air Liquide. This transaction represents a strategic carve-out for Air Liquide, allowing the French industrial gas giant to refocus on its core activities while providing Schülke with the independent capital necessary for long-term expansion. Announced during the height of the COVID-19 pandemic, the deal saw increased competition from other major private equity firms (PAI Partners, Ardian) due to Schülke’s critical role in infection prevention. EQT’s vision for the company involves accelerating geographical expansion, enhancing its digital presence, and reinforcing its market leadership in the healthcare hygiene sector through a focused "stand-alone" strategy.

SCHÜLKE, which reported an EBITDA margin of in 2019, is valued in this transaction at an EV/EBITDA multiple of , representing a to the average currently observed in the Healthcare & Pharma sector (14.5x).

-> Deep-dive in Healthcare & Pharma market trends

Target

Founded in 1889, Schülke is a global leader in infection prevention and treatment solutions for the healthcare and life sciences industries. Headquartered in Norderstedt, the company specializes in high-quality disinfectants, antisepsis products, and wound care solutions, featuring iconic brands such as octenisept, kodan, and desderman. Its business model focuses on mission-critical hygiene for hospitals, pharmacies, and direct patient care channels. Under recent private equity ownership, the company underwent a major strategic repositioning to exit non-core personal care segments and focus entirely on healthcare. Schülke operates three production sites in Germany, France, and Brazil, and maintains market-leading positions in Central and Eastern Europe, Australia, and Brazil.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2019

2018

Other operations with SCHÜLKE

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
08/2023	ATHOS CONSORTIUM	SCHÜLKE	GERMANY	Medical Consumables

REFERENCES

Valuation range: EV 500M - 1.5b EUR

Revenue range: 250M - 500M EUR

EBITDA range: 50M - 100M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of SCHÜLKE by EQT PARTNERS are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Press release: view release

Target: schülke

Acquirer: eqt partners